Acoltremon (Tryptyr) for Dry Eye Disease: A Review of the TRPM8 Agonist Mechanism and Clinical Utility

Abstract

Dry Eye Disease (DED) is a multifactorial condition characterized by tear film instability, ocular surface inflammation, and neurosensory abnormalities. While the prevalence of DED is rising globally, affecting over 16 million adults in the US alone, treatment options have historically been limited to artificial tears or anti-inflammatory agents with delayed onset of action. Current therapies, such as calcineurin inhibitors and LFA-1 antagonists, effectively target inflammation but often fail to address the neurosensory component of the disease or provide rapid symptomatic relief. The recent FDA approval of Acoltremon (Tryptyr) introduces a first-in-class TRPM8 agonist that specifically targets the eye’s natural cooling sensors to stimulate tear production. This viewpoint analyzes the clinical utility of Acoltremon, arguing that its novel mechanism fills a critical gap in the "symptoms without signs" treatment paradigm and offers a distinct advantage in rapidity of onset compared to existing immunomodulators.